An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
This is an open-label, multi-center, global roll-over study designed to assess long term safety and provide continued treatment to participants who have previously participated in an asciminib Novartis sponsored study and who, in the opinion of the investigator, would benefit from continued treatment as in their parent study but are unable to access this treatment outside of the clinical study.
Key Inclusion Criteria:
Key Exclusion Criteria:
Participant has been discontinued from parent study treatment.
Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study.
Participant's ongoing treatment is currently approved and reimbursed at country level.
Pregnant or nursing (lactating) women.
Women of child-bearing potential, unless they are using highly effective methods of contraception and willing to continue while taking study treatment.
Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib unwilling to follow the relevant contraception requirements in the local prescribing information.
Applicable for participants on bosutinib treatment at the end of the CABL001A2301 and on other TKIs for CABL001A2202 study that switch to asciminib treatment:
Other protocol-defined Inclusion/Exclusion criteria may apply.
novartis.email@novartis.com1-888-669-6682
+41613241111
Ann Arbor, Michigan 48109 5271, United States
kwhitley@med.umich.edu
CABA, Buenos Aires C1221ADC, Argentina
Capital Federal, C1114AAN, Argentina
Xian, Shanxi 710004, China
Khoudh, 123, Oman
Jeollanam, 519763, South Korea
Santiago Compostela, A Coruna 15706, Spain
pascuals@mskcc.org646-497-9068
Jessica.Maner@usoncology.com+1 214 370 1000
sawahl2@mdanderson.org+1 713 792 2921
ekonkol@mcw.edu414-805-6803